Emily M. Leproust Sells 7,968 Shares of Twist Bioscience Co. (NASDAQ:TWST) Stock

Twist Bioscience Co. (NASDAQ:TWST) CEO Emily M. Leproust sold 7,968 shares of the stock in a transaction on Monday, November 11th. The shares were sold at an average price of $48.00, for a total value of $382,464.00. Following the sale, the chief executive officer now owns 581,584 shares of the company’s stock, valued at approximately $27,916,032. This represents a 1.35 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Twist Bioscience Stock Down 8.3 %

NASDAQ:TWST opened at $38.96 on Friday. The company has a 50 day moving average price of $43.90 and a 200-day moving average price of $45.88. Twist Bioscience Co. has a 1-year low of $18.80 and a 1-year high of $60.90.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of TWST. Thrivent Financial for Lutherans purchased a new position in shares of Twist Bioscience during the 3rd quarter valued at approximately $43,992,000. Fred Alger Management LLC raised its position in Twist Bioscience by 17.1% during the third quarter. Fred Alger Management LLC now owns 767,149 shares of the company’s stock worth $34,660,000 after acquiring an additional 112,272 shares during the period. Point72 Asset Management L.P. lifted its holdings in Twist Bioscience by 1,021.8% during the second quarter. Point72 Asset Management L.P. now owns 673,057 shares of the company’s stock valued at $33,168,000 after purchasing an additional 613,057 shares in the last quarter. Charles Schwab Investment Management Inc. grew its position in shares of Twist Bioscience by 4.9% in the third quarter. Charles Schwab Investment Management Inc. now owns 524,942 shares of the company’s stock valued at $23,717,000 after purchasing an additional 24,582 shares during the period. Finally, New York State Common Retirement Fund increased its stake in shares of Twist Bioscience by 1.8% during the third quarter. New York State Common Retirement Fund now owns 482,606 shares of the company’s stock worth $21,804,000 after purchasing an additional 8,529 shares in the last quarter.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on TWST shares. Evercore ISI increased their price target on Twist Bioscience from $52.00 to $56.00 and gave the company an “outperform” rating in a research note on Tuesday, October 1st. Leerink Partners lifted their target price on shares of Twist Bioscience from $45.00 to $48.00 and gave the stock a “market perform” rating in a research note on Thursday, October 17th. JPMorgan Chase & Co. upped their price target on shares of Twist Bioscience from $28.00 to $35.00 and gave the company an “underweight” rating in a research note on Monday, August 5th. Robert W. Baird boosted their price objective on shares of Twist Bioscience from $40.00 to $46.00 and gave the company an “outperform” rating in a report on Monday, August 5th. Finally, Barclays cut their target price on Twist Bioscience from $60.00 to $55.00 and set an “overweight” rating on the stock in a research report on Monday, August 5th. One analyst has rated the stock with a sell rating, one has issued a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $51.22.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.